Treatment Information

Back

Lung Cancer treatment details. Biologic therapy.

VU University Medical Center Amsterdam, Amsterdam, Netherlands.

Survival: monthsCountry:Netherlands
Toxiciy Grade:5City/State/Province:Amsterdam
Treatments:Biologic therapyHospital:VU University Medical Center Amsterdam
Drugs:Journal:Link
Date:Jun 2010

Description:

Patients:
This study involved 50 patients with advanced non-small cell lung cancer who had not received previous chemotherapy. The median patient age was 60 years and 56% were male.

Treatment:
Patients were treated with the biologic therapy agents erlotinib and sorafenib.

Toxicities:
There was 1 reported treatment-related death due to pulmonary hemorrhage. Grade 3 fatigue (16% of patients), hand-foot syndrome (16%), and diarrhea (14%) were also reported.

Results:
The median overall survival was 10.9 months.

Support:
This study was supported by Bayer Pharmaceuticals, makers of sorafenib.

Correspondence: Dr. Egbert F. Smit; email: [email protected]



Back